Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma

Jennifer Wiggins; Qiao Zhang; Yian Zhang; Fatemeh Vand-Rajabpour; Douglas Hanniford; Linchen He; Yuting Lu; Jessica Kenney; Keimya Sadeghi; Diana Argibay; Irene Orlow; Klaus J. Busam; Cecilia Lezcano; Tim K. Lee; Li Luo; Ivan Gorlov; Christopher I. Amos; Marc S. Ernstoff; Venkatraman Seshan; Anne Ε. Cust; James S. Wilmott; Richard A Scolyer; Graham J. Mann; Allison Reiner; Caroline E. Kostrzewa; Eduardo Nagore; Pauline Funchain; Jennifer S. Ko; Sharon N. Edmiston; Kathleen Conway; Paul B. Googe; David W. Ollila; Jeffrey E. Lee; Judy R. Rees; Cheryl L. Thompson; Meg R. Gerstenblith; Marcus Bosenberg; Bonnie E. Gould Rothberg; Iman Osman; Yvonne M. Saenger; Adam Z. Reynolds; Tawny W. Boyce; Sheri L. Holmen; Shaofeng Yan; Elise K. Brunsgaard; Paul N. Bogner; Pei Fen Kuan; Nancy E. Thomas; Colin B. Begg; Ronglai Shen; Marianne Berwick; Yongzhao Shao; David Polsky; Eva Hernando

doi:10.1158/1078-0432.ccr-24-3785

Related publications

Article2021

Tumour gene expression signature in primary melanoma predicts long-term outcomes

Manik Garg, Dominique‐Laurent Couturier, Jérémie Nsengimana, Nuno A. Fonseca, Matthew Wongchenko, Yibing Yan, Martin Lauss, Göran Jönsson, Julia Newton‐Bishop, Christine Parkinson, Mark R. Middleton, D. Timothy Bishop, Sarah McDonald, Nikki Stefanos, John A. Tadross, Ismael A. Vergara, Serigne Lo, Felicity Newell, James S. Wilmott, John F. Thompson, Georgina V. Long, Richard A Scolyer, Pippa Corrie, David J. Adams, Alvis Brāzma, Roy Rabbie

Article2025

Rational use of adjuvant anti-PD-1: Multi-omics model of recurrence in stage III melanoma.

Tuba N. Gide, Nurudeen A. Adegoke, Michael Xie, Yizhe Mao, Grace H. Attrill, Nigel Maher, Robyn P.M. Saw, Ismael A. Vergara, Matteo S. Carlino, Serigne Lo, Inês Pires da Silva, Jorja Braden, Alexander M. Menzies, Richard A Scolyer, Georgina V. Long, James S. Wilmott

Article2016

Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis

Nicolas Jacquelot, María Paula Roberti, David Enot, Sylvie Rusakiewicz, Michaëla Semeraro, Sarah Jégou, Camila Flores, Lieping Chen, Byoung S. Kwon, Christophe Borg, Benjamin Weide, F. Aubin, Stéphane Dalle, Holbrook E. Kohrt, Maha Ayyoub, Guido Guido Kroemer, Aurélien Marabelle, Andréa Cavalcanti, Alexander Eggermont, Laurence Zitvogel

Article2022

A tool to predict survival outcomes and guide adjuvant immunotherapy recommendations for patients with stage II melanoma.

Alexander H. R. Varey, Georgina V. Long, Richard A Scolyer, Jeffrey E. Gershenwald, Julie M. Simon, John F. Thompson, Serigne Lo

Article2025

Supplementary Figures1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma

Jennifer Wiggins, Qiao Zhang, Yian Zhang, Fatemeh Vand-Rajabpour, Douglas Hanniford, Linchen He, Yuting Lu, Jessica Kenney, Keimya Sadeghi, Diana Argibay, Irene Orlow, Klaus J. Busam, Cecilia Lezcano, Tim K. Lee, Li Luo, Ivan Gorlov, Christopher I. Amos, Marc S. Ernstoff, Venkatraman Seshan, Anne Ε. Cust, James S. Wilmott, Richard A Scolyer, Graham J. Mann,